Mirvetuximab Soravtansine (Solution) provides a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC) for cancer and oncology research that specifically combines an FRα-directed monoclonal antibody with the maytansinoid DM4 payload, supporting targeted cytotoxicity and ADC studies.
Key Features and Benefits
- FRα-Targeting ADC: Combines an FRα-directed monoclonal antibody with the cytotoxic maytansinoid payload DM4.
- DM4 Payload: Contains a potent microtubule-disrupting maytansinoid used for targeted cytotoxicity research.
- Folate Receptor Alpha Recognition: Supports studies of FRα expression, antibody binding, internalization, and tumor-targeting mechanisms.
- Cleavable Linker: Uses a cleavable linker system that specifically supports intracellular release of active maytansinoid species.
- Targeted Payload Delivery: Supports investigation of antibody-mediated DM4 delivery to FRα-expressing cancer cells.
- Microtubule Disruption: DM4 interferes with microtubule function, specifically supporting studies of ADC-mediated cytotoxic responses.
- Solution Format: Provides Mirvetuximab Soravtansine in solution form specifically for convenient experimental use and assay preparation.
Applications
- FRα-Positive Cancer Research: Supports studies involving tumors with folate receptor alpha expression.
- Ovarian Cancer Research: Especially useful for investigating FRα-targeted ADC strategies in ovarian cancer models.
- ADC Research: Supports studies of antibody targeting, internalization, payload delivery, and cytotoxic activity.
- Folate Receptor Research: Useful for investigating FRα expression, cellular targeting, and receptor-mediated internalization.
- Targeted Cancer Research: Supports investigation of antibody-mediated delivery of maytansinoid payloads to cancer cells.
- Cell-Based Cancer Assays: Useful for evaluating FRα-dependent binding, internalization, and cellular responses.
- Mechanism-of-Action Studies: Supports investigation of FRα targeting and DM4-mediated microtubule disruption.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for antibody-drug conjugates and cytotoxic research materials. Maintain conditions that preserve protein and conjugate stability.
Mirvetuximab Soravtansine (Solution) combines FRα-directed antibody targeting with the microtubule-disrupting DM4 payload and specifically supports FRα-positive cancer, ovarian cancer, ADC, targeted drug delivery, and oncology research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
